Padcev/Keytruda Results Could Sweeten Potential Seagen/Merck Deal
Most Observers Still Want More Detailed Data From Urothelial Cancer Study
Seagen/Astellas announced Phase Ib/II trial data for the combination that could lead to an accelerated approval for the antibody-drug conjugate in first-line bladder cancer.
